美国医院住院的 2019 冠状病毒病（COVID-19）患者中的抗生素耐药感染。
Antibiotic-Resistant Infections Among Inpatients with Coronavirus Disease 2019 (COVID-19) in US Hospitals.
机构信息
Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
出版信息
Clin Infect Dis. 2022 Oct 3;75(Suppl 2):S294-S297. doi: 10.1093/cid/ciac517.
Abstract
We described bacterial/fungal coinfections and antibiotic-resistant infections among inpatients with a diagnosis of coronavirus disease 2019 (COVID-19) and compared findings in those with a diagnosis of influenza like illness. Less than 10% of inpatients with COVID-19 had bacterial/fungal coinfection. Longer lengths of stay, critical care stay, and mechanical ventilation contribute to increased incidence of hospital-onset infections among inpatients with COVID-19.
摘要
我们描述了患有 2019 年冠状病毒病（COVID-19）诊断的住院患者中的细菌/真菌感染和抗生素耐药感染，并比较了那些具有流感样疾病诊断的患者的发现。不到 10%的 COVID-19 住院患者有细菌/真菌感染。住院时间延长、入住重症监护病房和机械通气会增加 COVID-19 住院患者发生医院获得性感染的发生率。
相似文献
1
Antibiotic-Resistant Infections Among Inpatients with Coronavirus Disease 2019 (COVID-19) in US Hospitals.美国医院住院的 2019 冠状病毒病（COVID-19）患者中的抗生素耐药感染。
Clin Infect Dis. 2022 Oct 3;75(Suppl 2):S294-S297. doi: 10.1093/cid/ciac517.
2
Antibiotic Use and Bacterial Infection among Inpatients in the First Wave of COVID-19: a Retrospective Cohort Study of 64,691 Patients.COVID-19 第一波期间住院患者的抗生素使用与细菌感染：一项对 64691 例患者的回顾性队列研究。
Antimicrob Agents Chemother. 2021 Oct 18;65(11):e0134121. doi: 10.1128/AAC.01341-21. Epub 2021 Sep 7.
3
Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing.细菌和真菌合并感染冠状病毒的个体：一项支持 COVID-19 抗菌药物处方的快速综述。
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468. doi: 10.1093/cid/ciaa530.
4
Coronavirus disease 2019 (COVID-19) associated bacterial coinfection: Incidence, diagnosis and treatment.新型冠状病毒病 2019（COVID-19）相关细菌合并感染：发生率、诊断和治疗。
J Microbiol Immunol Infect. 2022 Dec;55(6 Pt 1):985-992. doi: 10.1016/j.jmii.2022.09.006. Epub 2022 Oct 7.
5
Empiric Antibacterial Therapy and Community-onset Bacterial Coinfection in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19): A Multi-hospital Cohort Study.2019冠状病毒病（COVID-19）住院患者的经验性抗菌治疗与社区获得性细菌合并感染：一项多中心队列研究
Clin Infect Dis. 2021 May 18;72(10):e533-e541. doi: 10.1093/cid/ciaa1239.
6
Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting.COVID-19 住院患者的细菌和真菌感染：英国二级保健机构中的回顾性队列研究。
Clin Microbiol Infect. 2020 Oct;26(10):1395-1399. doi: 10.1016/j.cmi.2020.06.025. Epub 2020 Jun 27.
7
Development and validation of machine learning-based models for predicting healthcare-associated bacterial/fungal infections among COVID-19 inpatients: a retrospective cohort study.基于机器学习的模型用于预测COVID-19住院患者医疗相关细菌/真菌感染的开发与验证：一项回顾性队列研究
Antimicrob Resist Infect Control. 2024 Apr 14;13(1):42. doi: 10.1186/s13756-024-01392-7.
8
State-of-the-art review of secondary pulmonary infections in patients with COVID-19 pneumonia.COVID-19 肺炎患者继发肺部感染的研究进展。
Infection. 2021 Aug;49(4):591-605. doi: 10.1007/s15010-021-01602-z. Epub 2021 Mar 11.
9
Risk factors and outcomes associated with community-onset and hospital-acquired coinfection in patients hospitalized for coronavirus disease 2019 (COVID-19): A multihospital cohort study.与 COVID-19 住院患者的社区获得性和医院获得性合并感染相关的风险因素和结局：一项多医院队列研究。
Infect Control Hosp Epidemiol. 2022 Sep;43(9):1184-1193. doi: 10.1017/ice.2021.341. Epub 2021 Jul 26.
10
The Unrecognized Threat of Secondary Bacterial Infections with COVID-19.新冠病毒二次细菌性感染的未被识别威胁。
mBio. 2020 Aug 7;11(4):e01806-20. doi: 10.1128/mBio.01806-20.
引用本文的文献
1
Empiric Azithromycin in COVID-19 Impacts the Respiratory Microbiome and Antimicrobial Resistome without Anti-inflammatory Benefit.COVID-19患者使用经验性阿奇霉素会影响呼吸道微生物组和抗菌药物耐药组，且无抗炎益处。
Res Sq. 2025 Jun 20:rs.3.rs-6875205. doi: 10.21203/rs.3.rs-6875205/v1.
2
Trends in Incidence and Epidemiology of Methicillin-Resistant Bacteremia, Six Emerging Infections Program Surveillance Sites, 2005-2022.2005 - 2022年六个新发感染项目监测点耐甲氧西林菌血症的发病率及流行病学趋势
Open Forum Infect Dis. 2025 May 12;12(6):ofaf282. doi: 10.1093/ofid/ofaf282. eCollection 2025 Jun.
3
Antimicrobial-Resistant Infections in Hospitalized Patients.住院患者的抗菌药物耐药性感染
JAMA Netw Open. 2025 Mar 3;8(3):e2462059. doi: 10.1001/jamanetworkopen.2024.62059.
4
Microbial dynamics and pulmonary immune responses in COVID-19 secondary bacterial pneumonia.新冠病毒二次细菌性肺炎中的微生物动态和肺部免疫反应。
Nat Commun. 2024 Oct 29;15(1):9339. doi: 10.1038/s41467-024-53566-x.
5
Ecologic analysis of antimicrobial use in South Carolina hospitals during 2020-2022.2020 - 2022年南卡罗来纳州医院抗菌药物使用情况的生态分析。
Antimicrob Steward Healthc Epidemiol. 2023 Dec 12;3(1):e232. doi: 10.1017/ash.2023.496. eCollection 2023.
6
Early empiric antibiotic use in COVID-19 patients: results from the international VIRUS registry.COVID-19 患者早期经验性使用抗生素：来自国际 VIRUS 登记处的结果。
Int J Infect Dis. 2024 Mar;140:39-48. doi: 10.1016/j.ijid.2023.12.006. Epub 2023 Dec 19.
7
Blood Stream Infections in COVID-19 Patients From a Tertiary Care Center in Lebanon: Causative Pathogens and Rates of Multi-Drug Resistant Organisms.黎巴嫩一家三级医疗中心的新冠病毒感染患者的血流感染：致病病原体和多重耐药生物体的发生率
Mayo Clin Proc Innov Qual Outcomes. 2023 Nov 24;7(6):556-568. doi: 10.1016/j.mayocpiqo.2023.10.001. eCollection 2023 Dec.
8
Bacterial coinfection and antibiotic resistance in hospitalized COVID-19 patients: a systematic review and meta-analysis.COVID-19 住院患者的细菌合并感染和抗生素耐药性：系统评价和荟萃分析。
PeerJ. 2023 Apr 26;11:e15265. doi: 10.7717/peerj.15265. eCollection 2023.
9
Point Prevalence Survey of Antimicrobial Use during the COVID-19 Pandemic among Different Hospitals in Pakistan: Findings and Implications.巴基斯坦不同医院在新冠疫情期间抗菌药物使用情况的现况调查：结果与启示
Antibiotics (Basel). 2022 Dec 30;12(1):70. doi: 10.3390/antibiotics12010070.
10
Increasing Consumption of Antibiotics during the COVID-19 Pandemic: Implications for Patient Health and Emerging Anti-Microbial Resistance.新冠疫情期间抗生素使用量增加：对患者健康及新出现的抗菌药物耐药性的影响
Antibiotics (Basel). 2022 Dec 28;12(1):45. doi: 10.3390/antibiotics12010045.
Zotero 插件